. 2018 May 1;10:44. doi: 10.1186/s13195-018-0363-1

Table 3.

Summary of data analysis of changes in MMSE and five neuropsychometric tests reflecting parieto-occipital function

	Change from baseline of first treatment period to baseline visit of second treatment period (test of carry-over from baseline values)			First treatment period: change from baseline visit to week 6 visit			First treatment period: change from baseline visit to week 12 visit
	Donepezil (n = 8), mean (SD)	Placebo (n = 10), mean (SD)	Difference (95% CI)	Donepezil (n = 8), mean (SD)	Placebo (n = 10), mean (SD)	Difference (95% CI)	Donepezil (n = 8), mean (SD)	Placebo (n = 10), mean (SD)	Difference (95% CI)
MMSE	2.5 (1.4)	−0.2 (1.7)	2.7 (1.3, 4.0)	1.0 (3.1)	−1.5 (2.4)	2.5 (0.1, 5.0)	1.5 (2.7)	−0.5 (2.4)	2.0 (−0.1, 4.5)
Simple calculation	−0.9 (0.7)^a	0.6 (1.1)^b	−1.5 (−2.6, –0.8)^c	−0.1 (0.7)^a	− 0.1 (0.8)^b	–0.0 (−0.7, 0.8)^c	0.0 (1.3)^a	0.4 (1.1)^b	−0.4 (−1.4, 0.8)^c
				Donepezil vs placebo 6-week comparison			Donepezil vs placebo 12-week comparison
				Donepezil first (n = 8), mean (SD)	Placebo first (n = 10), mean (SD)	Combined (n = 18), mean (95% CI)	Donepezil first (n = 8), mean (SD)	Placebo first (n = 10), mean (SD)	Combined (n = 18), mean (95% CI)
Number location	−1.0 (2.2)	−0.9 (1.3)	−0.1 (−1.7, 1.5)	0.8 (1.8)	0.2 (1.5)	0.5 (− 0.1, 1.5)	0.0 (2.4)^a	0.7 (2.4)	0.4 (−0.8, 1.4)^a
Letter cancellation	−0 (25)^a	2 (21)	−2 (−22, 19)^a	−7 (39)	−3 (15)	−5 (−19, 8)	−14 (35)^a	−1 (14)	−8 (−23, 4)^a
Dot counting	−0.3 (1.5)^a	−1.0 (2.4)^a	0.7 (−1.4, 2.3)^b	1.3 (1.8)	−0.2 (1.3)^a	0.5 (−0.2, 1.2)^a	1.3 (0.8)^a	−0.1 (1.7)	0.6 (−0.1, 1.1)^a
Digit span	0.3 (1.5)^b	0.0 (1.3)^b	0.3 (−0.9, 2.0)^d	0.6 (1.9)	0.1 (1.6)	0.4 (−0.4, 1.2)	0.0 (1.0)^a	−1 (0.8)	−0.5 (−0.9, −0.1)^a

CI confidence interval, MMSE Mini-Mental State Examination, SD standard deviation

^aOne missing value

^bTwo missing values

^cThree missing values

^dFour missing values